MassCATS is a collaboration of MGH and the MLSC, representing a consortium of pharma partners interested in supporting pre-competitive studies related to Alzheimer’s and neurodegenerative diseases.
Eligibility & Evaluation
Consortium members have pooled resources to fund research into chronic and debilitating neurological diseases. Applications are open for the 9th round of the program and are due by September 3, 2021.
The intent of the program is to identify or validate targets that may not have sufficient knowledge about them or sufficient preliminary data to support a deeper investment by pharma or other vendors; this is meant to be interpreted broadly. One example is: “what is the most important experiment that can be done to convince yourself that the target is related to the human biology of AD”; another example is “what method of platform needs to be developed to be able to answer questions about putative targets?” The projects are intended to be 6 month-1 year in duration, and explicitly are not postdoc fellowships but experiments, even if high risk, directed at moving the field forward. Applications from scientists who have not been involved in neurodegenerative disease research per se is encouraged.
For Round 9: We continue to invite applications from scientists from all fields who want to participate. In addition to this “open ended” invitation, the current round is piloting requests for proposals in one of four areas of investigation:
- Genetic “hits”
- Astrocyte Biology
If you are interested in applying, please email firstname.lastname@example.org with the subject MassCATS Round 9.
Impact on the Ecosystem
In July of 2013, the MLSC announced the first round awardees including three grants focused on Alzheimer’s Disease, two grants focused on neuropathic pain, and one grant each focused on Multiple Sclerosis and Parkinson’s Disease. For this second round, the Consortium has expanded the diseases of interest and is seeking proposals focused on neurodegenerative and neuroinflammatory diseases (such as AD, PD, MS, Huntington’s, ALS), neuropathic pain and treatment-resistant depression.
Connect with us to Learn More
If you have any questions regarding the application process, e-mail: email@example.com.